spironolactone has been researched along with Diarrhea in 14 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 9.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia." | 7.71 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. ( Berry, C; McMurray, JJ, 2001) |
| "This study demonstrated that endogenous aldosterone, as determined by its transient competitive block by spironolactone, caused significant sodium and chloride retention during naturally acquired cholera." | 7.65 | Effect of spironolactone on stool electrolyte losses during human cholera. ( Chen, LC; Guerrant, RL; Rohde, JE, 1972) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 5.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia." | 3.71 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. ( Berry, C; McMurray, JJ, 2001) |
| "Severe dehydration and watery diarrhea were induced by administering diuretics (furosemide, hydrohlorothiazide, spironolactone) and sucrose solution." | 3.70 | Use of peripheral temperature and core-peripheral temperature difference to predict cardiac output in dehydrated calves housed in a thermoneutral environment. ( Constable, PD; Foreman, JH; Morin, DE; Thurmon, JC; Walker, PG, 1998) |
| "5 mL/kg of body weight (BW), PO], sucrose (2 g/kg in a 20% aqueous solution, p." | 3.70 | A reliable, practical, and economical protocol for inducing diarrhea and severe dehydration in the neonatal calf. ( Constable, PD; Drackley, JK; Foreman, JH; Morin, DE; Thurmon, JC; Walker, PG, 1998) |
| "This study demonstrated that endogenous aldosterone, as determined by its transient competitive block by spironolactone, caused significant sodium and chloride retention during naturally acquired cholera." | 3.65 | Effect of spironolactone on stool electrolyte losses during human cholera. ( Chen, LC; Guerrant, RL; Rohde, JE, 1972) |
| "In conclusion, hypokalemia is extremely common in patients presenting with VT/VF, much more so than in patients with CHF alone." | 1.56 | Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study). ( Basil, A; Cooper, JM; Gangireddy, C; Greenberg, RM; Laslett, DB; Whitman, IR; Yesenosky, GA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Laslett, DB | 1 |
| Cooper, JM | 1 |
| Greenberg, RM | 1 |
| Yesenosky, GA | 1 |
| Basil, A | 1 |
| Gangireddy, C | 1 |
| Whitman, IR | 1 |
| Krum, H | 1 |
| Nolly, H | 1 |
| Workman, D | 1 |
| He, W | 1 |
| Roniker, B | 2 |
| Krause, S | 2 |
| Fakouhi, K | 1 |
| White, WB | 1 |
| Duprez, D | 1 |
| St Hillaire, R | 1 |
| Kuse-Hamilton, J | 1 |
| Weber, MA | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
| Asano, T | 1 |
| Maruyama, K | 1 |
| Jinbo, O | 1 |
| Tsumura, H | 1 |
| Furuya, F | 1 |
| Morita, T | 1 |
| Hirayama, T | 1 |
| Wenzl, HH | 1 |
| Fine, KD | 1 |
| Santa Ana, CA | 1 |
| Porter, JL | 1 |
| Fordtran, JS | 1 |
| Stepan, VM | 1 |
| Hammer, HF | 1 |
| Krejs, GJ | 1 |
| Constable, PD | 2 |
| Walker, PG | 2 |
| Morin, DE | 2 |
| Foreman, JH | 2 |
| Thurmon, JC | 2 |
| Drackley, JK | 1 |
| Berry, C | 1 |
| McMurray, JJ | 1 |
| Nemoto, H | 1 |
| Kurihara, T | 1 |
| Wortsman, J | 1 |
| Soler, NG | 1 |
| Greenblatt, DJ | 1 |
| Koch-Weser, J | 1 |
| Guerrant, RL | 1 |
| Chen, LC | 1 |
| Rohde, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Diarrhea
| Article | Year |
|---|---|
[Periodic paralysis secondary to urinary or gastrointestinal potassium loss].
Topics: Animals; Diagnosis, Differential; Diarrhea; Digestive System; Drug Therapy, Combination; Humans; Hyp | 2001 |
3 trials available for spironolactone and Diarrhea
| Article | Year |
|---|---|
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiot | 2002 |
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe | 2003 |
Effect of fludrocortisone and spironolactone on sodium and potassium losses in secretory diarrhea.
Topics: Adult; Aldosterone; Body Weight; Cathartics; Diarrhea; Electrolytes; Feces; Female; Fludrocortisone; | 1997 |
10 other studies available for spironolactone and Diarrhea
| Article | Year |
|---|---|
Electrolyte Abnormalities in Patients Presenting With Ventricular Arrhythmia (from the LYTE-VT Study).
Topics: Aged; Cardiomyopathies; Case-Control Studies; Diarrhea; Diuretics; Female; Heart Failure; Humans; Hy | 2020 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
A girl having congenital chloride diarrhea treated with spironolactone for seven years.
Topics: Child; Chlorides; Diarrhea; Female; Humans; Spironolactone | 1994 |
Hyperkalaemia and diarrhoea in a patient with surreptitious ingestion of potassium sparing diuretics.
Topics: Chronic Disease; Diarrhea; Diuretics; Female; Humans; Hydrochlorothiazide; Hyperaldosteronism; Hyper | 1997 |
Use of peripheral temperature and core-peripheral temperature difference to predict cardiac output in dehydrated calves housed in a thermoneutral environment.
Topics: Animals; Animals, Newborn; Blood Pressure; Body Temperature; Cardiac Output; Cattle; Cattle Diseases | 1998 |
A reliable, practical, and economical protocol for inducing diarrhea and severe dehydration in the neonatal calf.
Topics: Animals; Animals, Newborn; Blood Glucose; Blood Proteins; Body Temperature; Body Weight; Cattle; Col | 1998 |
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
Topics: Aged; Diarrhea; Diuretics; Fatal Outcome; Heart Arrest; Heart Failure; Humans; Hyperkalemia; Male; M | 2001 |
Mitotane. Spironolactone antagonism in Cushing's syndrome.
Topics: Aged; Cushing Syndrome; Diarrhea; Female; Humans; Hypokalemia; Mitotane; Nausea; Spironolactone | 1977 |
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
Topics: Adult; Aged; Blood Urea Nitrogen; Coma; Dehydration; Diarrhea; Female; Gynecomastia; Headache; Heart | 1973 |
Effect of spironolactone on stool electrolyte losses during human cholera.
Topics: Adult; Aldosterone; Chlorides; Cholera; Diarrhea; Feces; Humans; Male; Potassium; Sodium; Spironolac | 1972 |